Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Video Center

Published: 16 March 2016

Recent Videos: ASCO Palliative and Supportive Care Conference Coverage

There have been no new videos in this category within the last 12 months.

Related Videos

video-image

Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018

video-image

Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer

video-image

Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients

video-image

Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer

video-image

Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

video-image

Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data

video-image

Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer

video-image

Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer

video-image

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

video-image

Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Daniel P. Petrylak, MD, offers opinion on the POUT study presented at ASCO GU 2018

video-image

Daniel P. Petrylak, MD, on molecular characterization & bladder subtyping in bladder cancer

video-image

Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer

video-image

Naomi B. Haas, MD, on how patient characteristics play a role in sequencing in metastatic RCC

video-image

Naomi B. Haas, MD, on how immunotherapies are being integrated into kidney cancer treatment

video-image

Naomi B. Haas, MD, explains how cabozantinib is being integrated into treatment of renal cell cancer

video-image

Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, outlines the results of the POUT study presented at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, on molecular characterization & bladder subtyping data

video-image

Peter C. Black, MD, FACS, FRCSC, regarding checkpoint blockade in non-muscle invasive bladder cancer

video-image

Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy

video-image

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018

video-image

Thomas Powles, MD, MBBS, MRCP, regarding immunotherapy & chemotherapy combinations in bladder cancer

video-image

William K. Oh, MD, on abiraterone acetate fine particle formulation

video-image

William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer

video-image

William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients

video-image

Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy

video-image

Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer

video-image

Christopher J. Kane MD, FACS, on how the field of imaging is evolving

video-image

Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment

video-image

Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms

video-image

Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer

video-image

Peter C. Black, MD, FACS, FRCSC, on impact of The Cancer Genome Atlas Project in bladder cancer

video-image

Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer

video-image

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer

video-image

Daniel P. Petrylak, MD, outlines overall survival and immune responses from the STRIDE study

video-image

Daniel P. Petrylak, MD, on the Phase I data of enfortumab vedotin in mUC patients from ASCO GU 2018

video-image

Naomi B. Haas, MD, offers opinion on the optimal sequencing of agents in treatment of RCC

video-image

Naomi B. Haas, MD, considers the role of TKIs in the treatment of renal cell cancer

video-image

Naomi B. Haas, MD, on what clinical evidence can tell us about the adjuvant treatment of RCC

video-image

Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018

video-image

Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment

video-image

Daniel J. George, MD, regarding toxicity concerns when using sunitinib in RCC

video-image

Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC

video-image

Peter C. Black, MD, FACS, FRCSC, considers preferred checkpoint inhibitors for urothelial carcinoma

video-image

Peter C. Black, MD, FACS, FRCSC, on the usefulness of molecular markers in bladder cancer treatment

video-image

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms

video-image

Thomas Powles, MD, MBBS, MRCP, on the evolving landscape of metastatic bladder cancer

video-image

Thomas Powles, MD, MBBS, MRCP, considers molecular markers and muscle-invasive bladder cancer

video-image

William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms

video-image

William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018

video-image

Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer

video-image

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

video-image

Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study

video-image

Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018

video-image

Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer

video-image

Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer

video-image

Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer

video-image

Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer

video-image

Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer

video-image

Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer